16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          18F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high levels of 18F-THK5351 retention in brain regions thought to contain negligible concentrations of PHF raise questions about the interpretation of the positron emission tomography (PET) signals, particularly given previously described interactions between quinolone derivatives and monoamine oxidase B (MAO-B). Here, we tested the effects of MAO-B inhibition on 18F-THK5351 brain uptake using PET and autoradiography.

          Methods

          Eight participants (five mild cognitive impairment, two Alzheimer’s disease, and one progressive supranuclear palsy) had baseline 18F-AZD4694 and 18F-THK5351 scans in order to quantify brain amyloid and PHF load, respectively. A second 18F-THK5351 scan was conducted 1 week later, 1 h after a 10-mg oral dose of selegiline. Three out of eight patients also had a third 18F-THK5351 scan 9–28 days after the selegiline administration. The primary outcome measure was standardized uptake value (SUV), calculated using tissue radioactivity concentration from 50 to 70 min after 18F-THK5351 injection, normalizing for body weight and injected radioactivity. The SUV ratio (SUVR) was determined using the cerebellar cortex as the reference region. 18F-THK5351 competition autoradiography studies in postmortem tissue were conducted using 150 and 500 nM selegiline.

          Results

          At baseline, 18F-THK5351 SUVs were highest in the basal ganglia (0.64 ± 0.11) and thalamus (0.62 ± 0.14). In the post-selegiline scans, the regional SUVs were reduced on average by 36.7% to 51.8%, with the greatest reduction noted in the thalamus (51.8%) and basal ganglia (51.4%). MAO-B inhibition also reduced 18F-THK5351 SUVs in the cerebellar cortex (41.6%). The SUVs remained reduced in the three patients imaged at 9–28 days. Tissue autoradiography confirmed the effects of MAO-B inhibition on 18F-THK5351 uptake.

          Conclusions

          These results indicate that the interpretation of 18F-THK5351 PET images, with respect to tau, is confounded by the high MAO-B availability across the entire brain. In addition, the heterogeneous MAO-B availability across the cortex may limit the interpretation of 18F-THK5351 scans using reference region methods.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Automatic "pipeline" analysis of 3-D MRI data for clinical trials: application to multiple sclerosis.

          The quantitative analysis of magnetic resonance imaging (MRI) data has become increasingly important in both research and clinical studies aiming at human brain development, function, and pathology. Inevitably, the role of quantitative image analysis in the evaluation of drug therapy will increase, driven in part by requirements imposed by regulatory agencies. However, the prohibitive length of time involved and the significant intraand inter-rater variability of the measurements obtained from manual analysis of large MRI databases represent major obstacles to the wider application of quantitative MRI analysis. We have developed a fully automatic "pipeline" image analysis framework and have successfully applied it to a number of large-scale, multicenter studies (more than 1,000 MRI scans). This pipeline system is based on robust image processing algorithms, executed in a parallel, distributed fashion. This paper describes the application of this system to the automatic quantification of multiple sclerosis lesion load in MRI, in the context of a phase III clinical trial. The pipeline results were evaluated through an extensive validation study, revealing that the obtained lesion measurements are statistically indistinguishable from those obtained by trained human observers. Given that intra- and inter-rater measurement variability is eliminated by automatic analysis, this system enhances the ability to detect small treatment effects not readily detectable through conventional analysis techniques. While useful for clinical trial analysis in multiple sclerosis, this system holds widespread potential for applications in other neurological disorders, as well as for the study of neurobiology in general.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.

            Astrocytes colocalize with fibrillar amyloid-β (Aβ) plaques in postmortem Alzheimer disease (AD) brain tissue. It is therefore of great interest to develop a PET tracer for visualizing astrocytes in vivo, enabling the study of the regional distribution of both astrocytes and fibrillar Aβ. A multitracer PET investigation was conducted for patients with mild cognitive impairment (MCI), patients with mild AD, and healthy controls using (11)C-deuterium-L-deprenyl ((11)C-DED) to measure monoamine oxidase B located in astrocytes. Along with (11)C-DED PET, (11)C-Pittsburgh compound B ((11)C-PIB; fibrillar Aβ deposition), (18)F-FDG (glucose metabolism), T1 MRI, cerebrospinal fluid, and neuropsychologic data were acquired from the patients. (11)C-DED PET was performed in MCI patients (n = 8; mean age ± SD, 62.6 ± 7.5 y; mean Mini Mental State Examination, 27.5 ± 2.1), AD patients (n = 7; mean age, 65.1 ± 6.3 y; mean Mini Mental State Examination, 24.4 ± 5.7), and healthy age-matched controls (n = 14; mean age, 64.7 ± 3.6 y). A modified reference Patlak model, with cerebellar gray matter as a reference, was chosen for kinetic analysis of the (11)C-DED data. (11)C-DED data from 20 to 60 min were analyzed using a digital brain atlas. Mean regional (18)F-FDG uptake and (11)C-PIB retention were calculated for each patient, with cerebellar gray matter as a reference. ANOVA analysis of the regional (11)C-DED binding data revealed a significant group effect in the bilateral frontal and bilateral parietal cortices related to increased binding in the MCI patients. All patients, except 3 with MCI, showed high (11)C-PIB retention. Increased (11)C-DED binding in most cortical and subcortical regions was observed in MCI (11)C-PIB+ patients relative to controls, MCI (11)C-PIB (negative) patients, and AD patients. No regional correlations were found between the 3 PET tracers. Increased (11)C-DED binding throughout the brain of the MCI (11)C-PIB+ patients potentially suggests that astrocytosis is an early phenomenon in AD development.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Inhibition of monoamine oxidase B in the brains of smokers.

              The massive health problem associated with cigarette smoking is exacerbated by the addictive properties of tobacco smoke and the limited success of current approaches to cessation of smoking. Yet little is known about the neuropharmacological actions of cigarette smoke that contribute to smoking behaviour, or why smoking is so prevalent in psychiatric disorders and is associated with a decreased risk of Parkinson's disease. Here we report that brains of living smokers show a 40% decrease in the level of monoamine oxidase B (MAO B; EC 1.4.3.4) relative to non-smokers or former smokers. MAO B is involved in the breakdown of dopamine, a neurotransmitter implicated in reinforcing and motivating behaviours as well as movement. MAO B inhibition is therefore associated with enhanced activity of dopamine, as well as with decreased production of hydrogen peroxide, a source of reactive oxygen species. We propose that reduction of MAO B activity may synergize with nicotine to produce the diverse behavioural and epidemiological effects of smoking.
                Bookmark

                Author and article information

                Contributors
                kokpin22@gmail.com
                tharick.pascoal@gmail.com
                sulantha.s@gmail.com
                joseph.therriault1@gmail.com
                peter.ms.kang@gmail.com
                monica.shin1989@gmail.com
                marie.christine.guiot@mcgill.ca
                qi.guo@abbvie.com
                dragon1@med.tohoku.ac.jp
                robert.comley@abbvie.com
                gassan.massarweh@mcgill.ca
                jean-paul.soucy@mcgill.ca
                nookamura@med.tohoku.ac.jp
                serge.gauthier@mcgill.ca
                (+1) 514-761-6131 , pedro.rosa@mcgill.ca
                Journal
                Alzheimers Res Ther
                Alzheimers Res Ther
                Alzheimer's Research & Therapy
                BioMed Central (London )
                1758-9193
                31 March 2017
                31 March 2017
                2017
                : 9
                : 25
                Affiliations
                [1 ]GRID grid.14709.3b, Translational Neuroimaging Laboratory, , The McGill University Research Centre for Studies in Aging, ; 6825 LaSalle Boulevard, Verdun, Québec H4H 1R3 Canada
                [2 ]GRID grid.276809.2, Department of Neurology, , National Neuroscience Institute, ; 11 Jalan Tan Tock Seng, Singapore, 308433 Singapore
                [3 ]GRID grid.14709.3b, Alzheimer’s Disease Research Unit, , The McGill University Research Centre for Studies in Aging, McGill University, ; 6825 LaSalle Boulevard, Verdun, Québec H4H 1R3 Canada
                [4 ]GRID grid.14709.3b, Montreal Neurological Institute/Hospital, Department of Pathology, , McGill University Hospital Centre, ; 3801 University Street, Montreal, Québec H3A 2B4 Canada
                [5 ]GRID grid.431072.3, , AbbVie Inc., ; 1 North Waukegan Road, North Chicago, IL USA
                [6 ]GRID grid.69566.3a, Department of Pharmacology, , Tohoku University Graduate School of Medicine, ; 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575 Japan
                [7 ]GRID grid.14709.3b, , McConnell Brain Imaging Centre, McGill University, ; 3801 University Street, Montreal, Québec H3A 2B4 Canada
                [8 ]Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai, 981-8558 Japan
                [9 ]GRID grid.416102.0, , Montreal Neurological Institute, ; 3801 University Street, Montreal, Québec H3A 2B4 Canada
                [10 ]GRID grid.14709.3b, Department of Neurology and Neurosurgery, , McGill University, ; 3801 University Street, Montreal, Québec H3A 2B4 Canada
                Author information
                http://orcid.org/0000-0001-9116-1376
                Article
                253
                10.1186/s13195-017-0253-y
                5374697
                28359327
                91aad9b1-697b-4e71-aed1-e3b8a96f9ab0
                © The Author(s). 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 31 January 2017
                : 1 March 2017
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100000024, Canadian Institutes of Health Research;
                Award ID: MOP-11-51-31
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000957, Alzheimer's Association;
                Award ID: NIRG-12-92090, NIRP-12-259245
                Award Recipient :
                Funded by: Alan Tiffin Foundation
                Categories
                Research
                Custom metadata
                © The Author(s) 2017

                Neurology
                18f-thk5351 tau tracer,monoamine oxidase-b,selegiline,alzheimer’s disease,positron emission tomography

                Comments

                Comment on this article